Purple Biotech (PPBT) ehemals KTOV (Mkap $16 M) ( Cash $17 M) US Zulassungsantrag diesen Quartal (Seite 166)
eröffnet am 18.07.17 17:14:19 von
neuester Beitrag 31.03.24 12:32:14 von
neuester Beitrag 31.03.24 12:32:14 von
Beiträge: 1.796
ID: 1.257.452
ID: 1.257.452
Aufrufe heute: 4
Gesamt: 149.334
Gesamt: 149.334
Aktive User: 0
ISIN: US74638P1093 · WKN: A2QLTP · Symbol: 1YI1
0,6200
EUR
+12,73 %
+0,0700 EUR
Letzter Kurs 22.05.24 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
21.05.24 · globenewswire  |
25.04.24 · globenewswire |
28.03.24 · globenewswire |
14.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2460 | +49,94 | |
| 1,0800 | +28,56 | |
| 2,1800 | +27,49 | |
| 1,9900 | +20,61 | |
| 10.777,50 | +19,75 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 46,20 | -16,00 | |
| 0,5701 | -16,77 | |
| 2,5100 | -17,43 | |
| 2,2001 | -20,57 | |
| 0,6240 | -35,00 |
Beitrag zu dieser Diskussion schreiben
Feedback
Auf dem Weg ins Minus...traurig, aber wahr 🥳
Kleiner Nachtrag:
Ein paar Spekulationen in US-Foren gibts ja bzgl. einer Übernahme durch BMS...wäre wahrscheinlich für alle Beteiligten (und Aktionäre) die beste Lösung...🙄
Ein paar Spekulationen in US-Foren gibts ja bzgl. einer Übernahme durch BMS...wäre wahrscheinlich für alle Beteiligten (und Aktionäre) die beste Lösung...🙄
20 Mio. gehandelte Aktien bis jetzt, d.h. eigentlich der komplette Free-Float einmal 😳
Und dann nur läppische 17% im Plus?! Hier ist doch was faul, oder?! 🤨
Mein EK liegt bei 2 Euro, wenn der Kurs nur annähernd wieder jemals da hinkommen sollte, werde ich verkaufen...
Und dann nur läppische 17% im Plus?! Hier ist doch was faul, oder?! 🤨
Mein EK liegt bei 2 Euro, wenn der Kurs nur annähernd wieder jemals da hinkommen sollte, werde ich verkaufen...
Hattest ja ‘nen guten Riecher 👃, DWL33 😉
Außer daß es wohl bisschen mehr Aufschlag wie 10% sein werden...😏
Hoffe nur, das Kursplus wird nicht gleich wieder abverkauft wie die letzten Male...
Außer daß es wohl bisschen mehr Aufschlag wie 10% sein werden...😏
Hoffe nur, das Kursplus wird nicht gleich wieder abverkauft wie die letzten Male...
Antwort auf Beitrag Nr.: 60.210.377 von DWL33 am 27.03.19 16:24:00Opdivo ist es geworden und in der Spitze vorbörslich 1,63$, also fast 50% plus
Trading Spotlight
20F 26.03.2019 S. 162:
Conditions to the Completion of the Transactions
Each party’s obligation to complete the acquisition is subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the acquisition, of various conditions applicable to all or any one of the parties, (subject to certain exceptions set forth in the Acquisition Agreement), which include the following:
● each of the representations and warranties of each party will be true and correct in all respects on and as of the date of the Acquisition Agreement and as of the closing as if made at and as of the closing (other than such representations and warranties that are made as of a specified date, which representations and warranties will be true and correct in all respects as of such date) (the “Accuracy of Representations Closing Condition”);
● the other party to the Acquisition Agreement must have performed or complied with in all material respects all covenants and obligations in the Acquisition Agreement required to be performed or complied with by it on or before the closing of the acquisition (the “Compliance with Obligations Closing Condition”);
● shares constituting all of the issued and outstanding shares of capital stock of FameWave shall be transferred to Kitov pursuant to the terms of the Acquisition Agreement, pursuant to joinder agreements to this Agreement executed by each FameWave shareholder which did not yet sign the Acquisition Agreement, or in accordance with the bring-along provisions in FameWave’s governing documents effected by FameWave;
● All filings with, notices to and other consents of any governmental authority required to be made or obtained on or prior to the closing date of the Transaction in connection with the transactions contemplated by the Acquisition Agreement shall have been made or obtained and shall be in full force and effect and any waiting period under any applicable antitrust or competition law, regulation or other applicable law shall have expired or been terminated;
● Our shareholders must have approved the Transaction and the issuance of our securities to be issued in connection with the transactions;
● the TASE shall have issued its approval, authorization and listing consent for the ordinary shares underlying the our securities to be issued as part of the Transaction;
● Since the date of the Acquisition Agreement, there shall not have occurred any material adverse effects (as such are defined in the Acquisition Agreement);
● the execution by FameWave no later than March 31, 2019 of a joint clinical collaboration agreement, which is now in an advanced stage of negotiation with a major pharmaceutical company, for a planned Phase I/II study of CM-24 in combination with a PD-1 antibody in early 2020, with preliminary data expected in late 2020.
● the closing of the Reversion Agreement amongst FameWave, Merck Sharp & Dohme Corp. (“MSD”) and cCAM Biotherapeutics Ltd. (the MSD subsidiary currently holding the license to CM-24 from THM), transferring the CM-24 license and other related assets to FameWave, shall have occurred.
● We shall have approved the FameWave CEO Option;
Hier wird es wohl bis Monatsende eine Mitteilung über Kooperation mit wahrscheinlich Merck Keytruda oder vielleicht auch BMS Opdivo geben. Das sollte für schnelle 10% reichen wenn man vorbörslich handeln kann.
Conditions to the Completion of the Transactions
Each party’s obligation to complete the acquisition is subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the acquisition, of various conditions applicable to all or any one of the parties, (subject to certain exceptions set forth in the Acquisition Agreement), which include the following:
● each of the representations and warranties of each party will be true and correct in all respects on and as of the date of the Acquisition Agreement and as of the closing as if made at and as of the closing (other than such representations and warranties that are made as of a specified date, which representations and warranties will be true and correct in all respects as of such date) (the “Accuracy of Representations Closing Condition”);
● the other party to the Acquisition Agreement must have performed or complied with in all material respects all covenants and obligations in the Acquisition Agreement required to be performed or complied with by it on or before the closing of the acquisition (the “Compliance with Obligations Closing Condition”);
● shares constituting all of the issued and outstanding shares of capital stock of FameWave shall be transferred to Kitov pursuant to the terms of the Acquisition Agreement, pursuant to joinder agreements to this Agreement executed by each FameWave shareholder which did not yet sign the Acquisition Agreement, or in accordance with the bring-along provisions in FameWave’s governing documents effected by FameWave;
● All filings with, notices to and other consents of any governmental authority required to be made or obtained on or prior to the closing date of the Transaction in connection with the transactions contemplated by the Acquisition Agreement shall have been made or obtained and shall be in full force and effect and any waiting period under any applicable antitrust or competition law, regulation or other applicable law shall have expired or been terminated;
● Our shareholders must have approved the Transaction and the issuance of our securities to be issued in connection with the transactions;
● the TASE shall have issued its approval, authorization and listing consent for the ordinary shares underlying the our securities to be issued as part of the Transaction;
● Since the date of the Acquisition Agreement, there shall not have occurred any material adverse effects (as such are defined in the Acquisition Agreement);
● the execution by FameWave no later than March 31, 2019 of a joint clinical collaboration agreement, which is now in an advanced stage of negotiation with a major pharmaceutical company, for a planned Phase I/II study of CM-24 in combination with a PD-1 antibody in early 2020, with preliminary data expected in late 2020.
● the closing of the Reversion Agreement amongst FameWave, Merck Sharp & Dohme Corp. (“MSD”) and cCAM Biotherapeutics Ltd. (the MSD subsidiary currently holding the license to CM-24 from THM), transferring the CM-24 license and other related assets to FameWave, shall have occurred.
● We shall have approved the FameWave CEO Option;
Hier wird es wohl bis Monatsende eine Mitteilung über Kooperation mit wahrscheinlich Merck Keytruda oder vielleicht auch BMS Opdivo geben. Das sollte für schnelle 10% reichen wenn man vorbörslich handeln kann.
So sieht es aus! Der Kurs geht wohl in Richtung 1$ vielleicht noch etwas tiefer. Sabby sorgt schon dafür.
Warten auf die nächsten positiven Nachrichten ist angesagt.
Warten auf die nächsten positiven Nachrichten ist angesagt.
Antwort auf Beitrag Nr.: 59.725.194 von treehunter am 28.01.19 10:05:05Danke für die Info.
Antwort auf Beitrag Nr.: 59.724.918 von Visionaer13 am 28.01.19 09:34:35Da Dr. Waymack keine Informationen preisgibt, wird eine neue Anhörung festgesetzt werden. Datum keine Ahnung.
Durchsuchen
